|
- Basilea. com : Basilea
We are committed to developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions Basilea is located in the Basel area, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN) CEO David Veitch | Full-Year Report 2024 Play
- Who we are : Basilea
Basilea has about 150 employees We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial or fungal infections
- What we do : Basilea
Anti-infectives, specifically antifungals and antibiotics, is the key focus of Basilea’s strategy We have successfully brought two anti-infective drugs to the market: the antifungal Cresemba (isavuconazole) and the antibiotic Zevtera (ceftobiprole)
- News : Basilea
Basilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the United States in children with invasive aspergillosis and invasive mucormycosis
- Basilea initiates clinical phase 3 study with antifungal fosmanogepix . . .
Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections
- News : Basilea
Basilea hat das LptA-Antibiotika-Programm Anfang 2024 von der Spexis AG erworben Im April dieses Jahres gab Basilea bekannt, dass es einen ersten CARB-X-Zuschuss von bis zu USD 0 9 Mio zur Unterstützung früher präklinischer Aktivitäten erhalten hat
- Investor center : Basilea
At Basilea, we have performed a materiality analysis in 2023 that helped us to understand, which environmental, social, governance (ESG) and economic topics matter most in the context of Basilea’s business model
- News : Basilea
Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections
|
|
|